The drugstore chain’s stance is a response to federal officials informing Theranos that its deficiencies jeopardize patient health and safety.
In the wake of the news that federal officials have informed Theranos its deficiencies pose “immediate jeopardy to patient health and safety,” the medical-testing startup’s partnership with Walgreens is hitting a bump. On Thursday afternoon, the drugstore giant announced that it told Theranos to stop sending the clinical laboratory tests collected from 40 Theranos Wellness Centers at Walgreens pharmacy locations in Arizona to the startup’s lab in Newark, California, for analysis.
